Intratumoral epidermal growth factor receptor (EGFR) mutation status has been especially found to be a strong predictive factor in lung adenocarcinomas (AC) for the efficacy of EGFR-tyrosine kinase inhibitors (TKI) (3). The gene discussed is EGFR; the disease is lung adenocarcinoma.